FDA Recommends Scheduling 7-Hydroxymitragynine, Targets Concentrated Kratom Derivative Products

Why it matters

The FDA's move to schedule 7-OH could reshape the kratom industry, particularly the fast-growing market for concentrated extracts, gummies, and vape products — while leaving natural kratom leaf products in a legally distinct, less-regulated category.

The big picture

On July 29, 2025, the FDA announced its recommendation to schedule 7-hydroxymitragynine (7-OH) — a concentrated derivative of the kratom plant — under the Controlled Substances Act, following a comprehensive medical and scientific review. The FDA took care to distinguish between concentrated 7-OH products and natural kratom leaf, noting that 7-OH is present only in trace amounts in natural leaves but is synthetically concentrated in many commercial products.

Key findings

• FDA recommended scheduling 7-hydroxymitragynine (7-OH) under the Controlled Substances Act on July 29, 2025
• The agency cited 7-OH's strong opioid receptor binding with potency that may exceed morphine
• FDA distinguished concentrated 7-OH products (gummies, drink mixes, vapes) from natural kratom leaf products
• Poison center and law enforcement data showed a sharp increase in serious adverse events linked to concentrated 7-OH products
• FDA issued warning letters to companies marketing 7-OH products, stating they are not lawful dietary supplements and are considered adulterated or misbranded
• The DEA is now reviewing the recommendation; a public comment period is anticipated before final scheduling

What they say

FDA Commissioner Dr. Marty Makary stated: "We need regulation and public education to prevent another wave of the opioid epidemic."

Bottom line

**The FDA has drawn a regulatory line between natural kratom leaf and concentrated 7-OH derivative products — recommending federal scheduling of 7-OH while leaving natural kratom leaf in a separate category pending further DEA review.**